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Abstract. Acute myeloid leukemia (AML) accounts for 
~20% of pediatric leukemia cases. The prognosis of pediatric 
AML has been improved in recent decades, but it trails that 
of most other types of pediatric cancer, with mortality rates of 
30‑40%. Consequently, newer more targeted drugs are required 
for incorporation into treatment plans. These newer drugs 
selectively target AML cells with specific gene alterations. 
However, there are significant differences in genetic alterations 
between adult and pediatric patients with AML. In the present 
study, inexpensive and rapid next‑generation sequencing (NGS) 
of >150 cancer‑related genes was performed for matched diag‑
nostic, remission and relapse (if any) samples from 27 pediatric 
patients with AML. In this analysis, seven genes were recur‑
rently mutated. KRAS was mutated in seven patients, NRAS was 
mutated in three patients, and KIT, GATA1, WT1, PTPN11, JAK3 
and FLT3 were each mutated in two patients. Among patients 
with relapsed AML, six harbored KRAS mutations at diagnosis; 
however, four of these patients lost these mutations at relapse. 
Additionally, two genetic alterations (FLT3‑ITD and TP53 alter‑
ations) were detected among patients who eventually relapsed, 
and these mutations are reported to be adverse prognostic 
factors for adult patients with AML. This panel‑based, targeted 
sequencing approach may be useful in determining the genetic 
background of pediatric AML and improving the prediction of 
treatment response and detection of potentially targetable gene 
alterations. RAS pathway mutations were highly unstable at 
relapse; therefore, these mutations should be chosen as a target 
with caution. Incorporating this panel‑based NGS approach into 
the clinical setting may allow for a patient‑oriented strategy of 
precision treatment for childhood AML.
Introduction
Acute myeloid leukemia (AML) accounts for ~20% of all 
cases of pediatric leukemia (1). Although the prognosis of 
pediatric AML has improved in recent decades, it trails that 
of other types of pediatric cancer, as 30‑40% of children with 
AML eventually succumb to the disease (1‑3). The treatment 
strategies for pediatric AML include intensive multimodal 
chemotherapy with or without stem cell transplantation, and 
cytarabine and anthracyclines have remained the primary 
choices of chemotherapy for >30 years (1,2,4,5). As clinical 
outcomes have not improved, even with intensive contemporary 
chemotherapeutic regimens and/or stem cell transplantation, 
newer targeted drugs are required for incorporation into 
treatment plans (5,6).
Recently, various newer targeted therapies have emerged, 
most of which target AML cells with specific genetic altera‑
tions (7). Among them, FLT3 inhibitors, such as midostaurin 
and gilteritinib, and IDH inhibitors, such as enasidenib and 
ivosidenib have already been approved for use in clinical 
settings (7). These newer drugs selectively target AML cells 
with specific features; hence, the genomic characterization of 
AML cells is becoming increasingly important in the clinical 
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setting. Using next‑generation sequencing (NGS), several 
studies have reported on the value of performing NGS for 
adult patients with AML (8‑12). However, there are compara‑
tively fewer reports focusing on childhood AML, particularly 
in cases of relapsed AML (13,14).
In the present study, panel‑based, targeted NGS for the 
molecular characterization of AML cells from pediatric 
patients was retrospectively performed. The objective of this 
study was to determine whether it was possible to obtain 
clinically useful information for children with AML through 
this NGS approach.
Materials and methods
Patients. A total of 27 children aged 0‑18 years who were diag‑
nosed with AML between January 2000 and December 2017 
in Okayama University Hospital, Kochi Health Sciences 
Center, St. Marianna University School of Medicine Hospital 
or Hokkaido University Hospital were enrolled in the present 
study. The ratio of boys to girls was 17:10 in the present cohort 
and the median age at diagnosis was 6 years (range, 0 months 
to 15 years). The treatment protocols were diverse, including 
those from the Japanese Pediatric Leukemia/Lymphoma 
Study Group AML‑99 (15), AML‑05 (16) and AML‑12 
studies, and are listed in Table I. The standard chimeric 
fusion gene screening varied has changed over time in 
Japan. AML‑05 protocol included the PCR‑based detection 
of eight frequent chimeric gene fusions; RUNX1‑RUNXT1, 
CBFB‑MYH11, KMT2A‑MLLT3, KMT2A‑MLLT4, KMT2A‑ 
MLLT1, FUS‑ERG, NUP98‑HOXA9 and PML‑RARA, 
and the AML‑12 protocol included eight gene fusions; 
RUNX1‑RUNXT1,  CBFB‑M YH11,  KM T2A‑MLLT3, 
KMT2A‑MLLT4, BCR‑ABL, FUS‑ERG, NUP98‑NSD1 and 
PML‑RARA. In our previous study, the clinical courses of 
UPN 6 and UPN 25 was reported (17,18). The present study 
was performed in accordance with the Declaration of Helsinki 
and other applicable guidelines (19‑21). The present study was 
approved by the Institutional Ethics Committee of Okayama 
University Hospital, and informed consent was obtained the 
patients and/or their legal guardians.
DNA isolation. Somatic DNA was obtained from bone marrow 
samples at diagnosis and each episode of relapse, whereas 
germline DNA was obtained from a buccal swab or periph‑
eral blood in CR status. DNA was extracted using a QIAamp 
DNA Blood Mini kit (Qiagen, Inc.) and quantified using a 
NanoDrop 2000 (Thermo Fisher Scientific, Inc.) and a Qubit® 
2.0 Fluorometer (Thermo Fisher Scientific, Inc.) according to 
the manufacturers' protocol.
Targeted NGS approach. Targeted sequencing of 
>150 cancer‑related genes was performed as described 
previously (22‑24). The targeted gene lists are shown in 
Table SI and patient allocation is shown in Table SII. These 
gene panels were generated using an online design tool for 
HaloPlex (Agilent Technologies, Inc.), and target enrich‑
ment was performed using the HaloPlex standard protocol. 
Samples were then sequenced using MiSeq (Illumina, Inc.). 
Read alignment to the hg19 reference genome was performed 
using Burrows‑Wheeler Aligner (bio‑bwa.sourceforge.net) 
and variant calling was performed using SureCall version 3.0 
(Agilent Technologies, Inc.).
Variant prioritization and assessment of pathogenicity. 
Synonymous or non‑coding variants and single nucleotide 
polymorphisms reported with a frequency of >1% in various 
databases (dbSNP, 1000gp and Human Genetic Variation 
Database) were excluded. Variant bases that had >5 reads in 
each sample were used for the next step. Genetic variations 
that were constantly detected from diagnostic, remission and 
relapse samples with a variant allele frequency (VAF) ≥0.2 
were regarded as candidate germline alterations. Genetic alter‑
ations that were rarely detected, or not detected at all, from 
remission samples but were detected from diagnostic and/or 
relapse samples with a VAF ≥0.05 were regarded as candidate 
somatic alterations with reference to a previous study (25). To 
exclude the possibility of false‑positive findings, differences 
in VAF between normal and diagnostic/relapse samples were 
assessed using a Fisher's exact test. P<0.01 was considered 
to indicate a statistically significant difference. Finally, for 
germline and somatic alterations, the read quality was checked 
using IGV software version 2.3 (Broad Institute).
Results
Patient characteristics. The clinical information of the 
analyzed patients is shown in Table I. All patients were 
Japanese. The present cohort included one patient with 
Down‑syndrome (UPN 8) and no other patients had a known 
underlying congenital condition. Remission samples were 
obtained by buccal smear from patient No. 2 and the sample 
collection was performed during remission. All relapsed 
patients lost their first remission within 24 months; 6 out 
of 15 patients experienced their relapse within 12 months, 
which is considered to be an adverse prognostic factor for 
survival (26).
Descriptive results from sequencing runs. The average number 
of total reads was 1,917,277 (range, 998,341‑4,333,332) and 
the average read length was 116‑136. The read depth in 
analyzable target regions per sample ranged from 168‑757x. 
In total, 70.49‑97.51% of analyzable regions were covered by 
at least 20 reads, 66.72‑95.24% were covered by at least 50 
reads and 58.15‑91.05% were covered by at least 100 reads. 
These quality metrics data were obtained from analysis using 
SureCall version 3.0 software (Agilent Technologies, Inc.) and 
the details are shown in Table SII.
The results of NGS are shown in Table II. A total of 26 
single nucleotide variations (SNVs) and insertions/deletions 
(indels) were identified at diagnosis, and 22 SNVs and indels at 
relapse for 15 patients with relapsed AML, as well as 12 SNVs 
and indels for the leukemia samples of 12 patients without 
relapse.
Somatic genetic alterations at diagnosis and AML subtypes. In 
the present study, seven genes were recurrently mutated. KRAS 
was mutated in 7 patients, NRAS was mutated in 3 patients, 
and KIT, GATA1, WT1, PTPN11, JAK3 and FLT3 were each 
mutated in 2 patients. As previously reported, KIT was 
mutated in patients with core‑binding factor AML (UPN 19 
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Table II. Gene alterations detected at diagnosis and relapse.
A, Relapsed AML
UPN Disease subtype SNVs at diagnosis (VAF) SNVs at relapse (VAF)
  1 FAB M5 KRASp.G12V (0.296) None
  2 FAB M6 (RAEB) PTPN11p.G60V(0.83) PTPN11p.G60V(0.44)
  PTPN11 p.V45L (0.10)
  3 FAB M7 KRAS p.A146T (0.09) None
 (non‑Down‑syndrome)
  4 FAB M5 None None
  5 FAB M7 GATA1p.R270W (0.43) GATA1p.R270W(0.23)
 (non‑Down‑syndrome) KRAS p.G12A (0.43) KRAS p.G12A (0.19)
  IKZF1 p.F154Y (0.38)a IKZF1p.F154Y(0.17)a
  IKZF1p.L161H (0.38)a IKZF1p.F161H(0.17)a
  6 FAB M2 FLT3‑ITD (0.572) FLT3‑ITD (0.689)
  7 FAB M2 PTPN11 p.I479F (0.40)  PTPN11p.I479F (0.35)
  + c.1473‑1481dela + c.1473‑1481dela
  8 FAB M7 GATA1 p.P50fs (0.30) GATA1 p.P50fs (0.05)
 (non‑Down‑syndrome)
  9 FAB M4 KRAS p.G12V (0.41) MLH1p.A586S (0.06)a
  SMARCA4p.R979Q (0.06)a
10 FAB M5b KRAS p.G13D (0.32) RUNX1p.Q390fs(0.2)
11 FAB M1 GATA2 p.R362Q (0.11) CEBPAp.D63fs(0.37)a
  CEBPAp.Q312HR (0.99)a CEBPAp.Q312HR (0.39)a
12 T/Myeloid JAK3 p.L857P (0.10) JAK3 p.L857P (0.13)
  NOTCH1p.V1721E (0.33) NOTCH1p.V1721E (0.33)
  STAT5Bp.N642H(0.11) IL7R p.L243GTARCV (0.10)a
  NF1 p.L2317H (0.05)a VHL p.L85fs (0.11)
13 FAB M7 None None
 (non‑Down‑syndrome)
14 FAB M4 U2AF1 p.R35L (0.53) KRAS p.G12D (0.23)
  KRAS p.G12D (0.37)
15 T/Myeloid TP53 p.K164E (0.998) TP53 p.K164E (0.858)
  PHF6 p.R274fs (0.724) PHF6p.R274fs (0.611)
  NPM1 p.L287fs (0.579) NPM1 p.L287fs (0.53)
   MPLp.A486V(0.064)a
B, Non‑relapsed AML
UPN Disease subtype SNVs at diagnosis (VAF) SNVs at relapse (VAF)
16 FAB M3 None ‑
17 FAB M3 None ‑
18 FAB M5a None ‑
19 FAB M4Eo KIT p.D816Y (0.28) ‑
  WT1 p.H448Y (0.22)a ‑
  NRAS p.Q61K (0.08) ‑
20 FAB M2 JAK3 p.M511I (0.13) ‑
21 AML with None ‑
 myelodysplasia‑related
 changes
22 FAB M2 NRAS p.G13D (0.37) ‑
  WT1 p.D447N (0.34) ‑
23 FAB M2 NRAS p.Q61K (0.25) ‑
24 FAB M2 KRAS p.G12D (0.52) ‑
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and UPN 27), and GATA1 was mutated in patients with acute 
megakaryoblastic leukemia with or without Down‑syndrome 
(UPN 5 and UPN 8) (27‑29). The present cohort included 
2 patients with mixed‑phenotype acute leukemia, and these 
patients harbored mutations previously reported in a larger 
study (30). Other mutations were not apparently associated 
with a specific type of AML. Most detected mutations have 
been reported in the Catalogue Of Somatic Mutations In 
Cancer database (cancer.sanger.ac.uk/cosmic), but some altera‑
tions were not. These mutations were thought to be variants of 
Table II. Continued.
B, Non‑relapsed AML
UPN Disease subtype SNVs at diagnosis (VAF) SNVs at relapse (VAF)
25 FAB M5 None ‑
26 FAB M5 FLT3 p.D839G (0.21) ‑
  FLT3 p.Y591D (0.08) ‑
  FLT3 p.D839N (0.07) ‑
27 FAB M2 KIT p.N822K (0.43) ‑
aAlterations not reported in Catalogue of Somatic Mutations in Cancer. UPN, unique patient number; AML, acute myeloid leukemia; VAF, 
variable allele frequency; SNV, single nucleotide variation.
Table III. Prognostic genetic alterations at diagnosis according to the European LeukemiaNet guidelines.
UPN Low‑risk features Intermediate risk features High‑risk features.
  1 No KMT2A‑MLLT3 Complex karyotype
  2 No No No
  3 No No Complex karyotype
  4 No No No
  5 No No Complex karyotype
  6 No No FLT3‑ITD
  7 No No No
  8 No No No
  9 No No t(6;11)(q27;q23)
10 No t(9;11)(p22;q23) No
11 CEBPA p.Q312HR No No
12 No No No
13 No No Complex karyotype
14 No No Complex karyotype
15 No No TP53 p.K164E
16 PML‑RARA No No
17 PML‑RARA No No
18 No No KMT2A‑MLLT10
19 CBFB‑MYH11 No No
20 RUNX1‑RUNXT1 No No
21 No No No
22 CBFB‑MYH11 No No
23 RUNX1‑RUNXT1 No No
24 RUNX1‑RUNXT1 No No
25 No No No
26 No KMT2A‑MLLT3 No
27 RUNX1‑RUNXT1 No No
UPN, unique patient number.
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unknown significance and are indicated with a superscripted 
letter in Table II.
Prognostic genetic alterations detected at diagnosis. According 
to the European LeukemiaNet (ELN) guideline, several factors 
are associated with the prognosis of AML (31). Among these, 
two high‑risk genetic alterations (FLT3‑ITD in patient 6 and 
TP53 alteration in patient 15) and one low‑risk genetic altera‑
tion (CEBPA mutation in patient 11) were added to the known 
cytogenetic risk factors (Table III). According to the guidelines, 
RUNX1 or ASXL1 alterations are indicated not to be used as 
adverse prognostic markers if they are present concurrently 
with favorable‑risk AML subtypes. However, TP53 alterations 
are regarded as an independent adverse prognostic factor, thus 
UPN 15 was placed in the ELN high‑risk group. The gene 
alterations which were defined in the ELN guideline or recur‑
rently detected in the present study are summarized in Fig. 1.
Mutational changes between diagnosis and relapse. A total 
of 15 patients who experienced relapse were analyzed. Among 
these, six harbored KRAS mutations at diagnosis. However, 
four of the six patients lost these mutations at relapse. None 
of the patients gained new RAS pathway mutations at relapse.
UPN 11 had a CEBPA p.Q312HR insertion‑type alteration 
at diagnosis, and this alteration appeared to be homozygous as 
its VAF was notably high (0.99). At relapse however, the VAF 
of CEBPA p.Q312HR alteration decreased, and a new p.D53fs 
alteration appeared, leading to a ‘double hit’ status.
Germline variations. In the present study, matched samples at 
diagnosis, remission and relapse (if any) among patients with 
childhood AML was analyzed, and this approach enabled detec‑
tion of germline variations. Although candidates of germline 
variations were detected in 8 patients, none were regarded as 
pathogenic or likely pathogenic according to published recom‑
mendations (19,21). These candidate genes are listed in Table SIII.
Discussion
In the present study, matched samples obtained from pediatric 
patients with AML at diagnosis, remission and relapse (if 
any) were analyzed using a panel‑based NGS method. Several 
studies have reported the utility of NGS for analysis of AML in 
adult patients (8‑12). However, there are comparatively fewer 
reports focusing on childhood AML, particularly in cases of 
relapsed AML (13,14).
The utility of NGS should be discussed separately in adult 
and pediatric patients. As was shown in the present study, 
there are significant differences in genetic alterations between 
adult and pediatric patients with AML. Whereas mutations in 
epigenetic components or spliceosome complexes are common 
among adults with AML (11), these mutations were notably less 
common amongst children with AML, based on the results of 
the present study. However, large structural aberrations such 
as chromosomal translocations are more common amongst 
children with AML (11,14). As a result, disease stratification 
guidelines or newer drugs developed for adults with AML may 
not always be suitable for children.
The panel‑based NGS strategy has been used several times 
in our previous studies for hematological malignancies, and the 
results of this method have been compared with conventional 
approaches, such as the multiplex ligation‑dependent probe ampli‑
fication or Sanger sequencing in our previous studies (22‑24). 
Based on the panel‑based NGS approach, several prognostic 
genetic alterations for patients with AML were detected in the 
present study. The ELN guidelines identified several cytoge‑
netic alterations and a smaller number of genetic mutations as 
prognostic factors. In the present cohort, additional cytogenetic 
risk factors possessed prognostic implications than the genetic 
mutations. Using this approach, two high‑risk genetic mutations 
were detected amongst patients who relapsed but did not possess 
any cytogenetic risk factors (UPN 6 and UPN 15). Conversely, 
none of the non‑relapsed patients possessed adverse prognostic 
genetic mutations, and non‑relapsed patients were enriched in 
low risk genetic alternations defined in the ELN guidelines. 
Thus, it may be possible to more accurately predict the prognosis 
of patients with AML using this approach. However, as noted 
above, there are significant differences in genetic alterations 
between adult and pediatric patients with AML. Previous larger 
studies suggested that current guidelines, including the ELN 
guidelines, are not adequate for children with AML (14,32,33), 
thus, there is a need for the development of a pediatric‑specific 
guidelines for more precise stratification.
FLT3‑ITD has a prognostic impact in pediatric 
AML (34,35), and this alteration was detected using the panel‑ 
based NGS method. However, the clinical impact of FLT3‑ITD 
Figure 1. Gene alterations defined in ELN guidelines or recurrently detected in the present study. Distribution of relevant gene mutations. UPN, unique patient 
number; ELN, European LeukemiaNet; SCT, stem cell transplantation; CR1, first complete remission.
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has been reported to be modulated by other sequence aberra‑
tions (WT1 mutation, NUP98‑NSD1 or NPMI mutations for 
adult AML) (14,36). In this context, panel‑based sequencing 
may be more useful than conventional approaches that detect 
only FLT3‑ITD. However, the ELN guidelines recommend 
the use of DNA fragment analysis to determine the ratio of 
FLT3‑ITD and prognosis. To confirm the usefulness of the 
NGS approach, a direct comparison of standard procedures 
and the NGS approach is required.
The number of genes that should be assessed has increased; 
however, one large study found that a limited number of genes are 
recurrently mutated in pediatric patients with AML (14); where 
several genetic analytical methods, including whole‑genome and 
targeted DNA sequencing were performed. Mutations in only 
5 genes (FLT3, NPM1, WT1, CEBPA and KIT) were present in 
>5% of patients, and <40 gene mutations were reported in >2% 
of patients. This previous study illustrated the need to focus 
on these 40 genes to detect recurrent gene mutations in AML 
cells obtained from pediatric patients, and that panel‑based 
sequencing is an ideal approach in a clinical setting. Furthermore, 
Morita et al (37) reported that the clearance of somatic mutation 
at remission was associated with significantly improved survival 
and a lower risk of relapse. This strategy requires a sufficient 
read depth to detect mutations with a VAF <1%; contrarily, the 
approach used in the present study could not reach that read depth 
due to low throughput and relatively high number of targeted 
genes. Limiting the number of targeted genes to 40 recurrently 
mutated genes will increase the read depth and potentially enable 
detection of gene alterations with lower VAFs.
The panel‑based approach used in the present study also 
offers potentially useful information regarding targetable genetic 
alterations. Cytotoxic chemotherapy primarily based on cytara‑
bine and anthracyclines with or without stem cell transplantation 
has long been the mainstay of AML treatment (1). The curative 
rate of pediatric AML steadily improves with increasing doses of 
these drugs; however, this leads to substantial treatment‑related 
complications in vulnerable pediatric populations (1,16,26). 
Hence, newer targeted therapies are desired. These targeted 
drugs include midostaurin, gilteritinib, enasidenib and ivosidenib, 
which target leukemic cells with specific genetic alterations such 
as FLT3, KIT, MEK, DOT1L or BET alterations (5,6); hence, 
genomic characterization of AML cells is becoming increasingly 
important in the clinical setting. Among these potentially targe‑
table gene alterations, 6 patients had RAS pathway mutations at 
the time of AML diagnosis. However, in the present cohort, a 
notably high percentage of patients (four out of six cases, 66.7%) 
lost the KRAS mutations at relapse. Thus, RAS pathway muta‑
tions should be chosen with caution as treatment targets.
The present study has several limitations. First, the study 
was retrospective, and it was not possible to clarify whether 
dose increases in patients who had high‑risk features would 
improve their prognoses. Second, the method used in the 
present study has a disadvantage of comparatively low 
throughput. Third, potential false positives were excluded, 
thus several relevant genetic alterations may have been missed. 
To detect minor clones with low variant frequencies at diag‑
nosis, the number of genes to be targeted should be limited, as 
noted above. The genetic events including TP53 loss of hetero‑
zygosity in UPN 15 should have also been illustrated using 
other experiments, such as fluorescent in situ hybridization, 
but this could not be achieved due to the sample availability 
and quality. Relatively small patient numbers is another disad‑
vantage of the present study. Furthermore, the ELN guidelines 
were established for adult patients; hence its validity in a larger 
cohort of pediatric patients with AML requires validation.
In summary, the panel‑based targeted sequencing approach 
used in the present study may be useful for revealing the genetic 
background of pediatric AML, and may facilitate the precise 
prediction of patient prognosis and detection of druggable gene 
alterations. Incorporating this method into the clinical setting 
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